• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 15-12G filed by Arcellx Inc.

    5/8/26 4:12:59 PM ET
    $ACLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ACLX alert in real time by email
    15-12G 1 tm2613951d1_1512g.htm 15-12G

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 15

     

     

    CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION

    UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934

    OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)

    OF THE SECURITIES EXCHANGE ACT OF 1934.

     

    Commission File No. 001-41259

     

     

    Arcellx, Inc.

    (Exact name of registrant as specified in its charter)

     

     

    800 Bridge Parkway

    Redwood City, California 94065

    (240) 327-0630 

    (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

     

    Common Stock, par value $0.001 per share

    (Title of each class of securities covered by this Form)

     

    None

    (Titles of all other classes of securities for which a duty to file reports under Section 13(a) or 15(d) remains)

     

     

    Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

     

    Rule 12g-4(a)(1) x 
    Rule 12g-4(a)(2) ¨ 
    Rule 12h-3(b)(1)(i) x 
    Rule 12h-3(b)(1)(ii) ¨ 
    Rule 15d-6 ¨ 
    Rule 15d-22(b) ¨ 

     

    Approximate number of holders of record as of the certification or notice date: One holder.

     

     

     

     

     

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, Arcellx, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

     

        Arcellx, Inc.
           
    Date:  May 8, 2026 By:  /s/ Andrew D. Dickinson
          Andrew D. Dickinson
          President and Treasurer

     

     

    Get the next $ACLX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACLX

    DatePrice TargetRatingAnalyst
    2/12/2026$82.00Buy → Neutral
    Rothschild & Co Redburn
    1/7/2026$100.00Buy
    UBS
    12/22/2025$100.00Overweight
    Wells Fargo
    11/18/2025Peer Perform
    Wolfe Research
    10/16/2025$129.00Buy
    Stifel
    6/17/2025$110.00Buy
    Citigroup
    10/8/2024$109.00Buy
    Redburn Atlantic
    9/3/2024Overweight
    Cantor Fitzgerald
    More analyst ratings

    $ACLX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Carroll Jill to satisfy tax liability

    4 - Arcellx, Inc. (0001786205) (Issuer)

    4/28/26 6:22:20 PM ET
    $ACLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Behbahani Ali closing all direct ownership in the company (SEC Form 4) to satisfy tax liability

    4 - Arcellx, Inc. (0001786205) (Issuer)

    4/28/26 4:34:28 PM ET
    $ACLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director Ware Olivia C

    4 - Arcellx, Inc. (0001786205) (Issuer)

    4/28/26 4:31:18 PM ET
    $ACLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACLX
    SEC Filings

    View All

    SEC Form 15-12G filed by Arcellx Inc.

    15-12G - Arcellx, Inc. (0001786205) (Filer)

    5/8/26 4:12:59 PM ET
    $ACLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by Arcellx Inc.

    SCHEDULE 13D/A - Arcellx, Inc. (0001786205) (Subject)

    4/30/26 5:38:06 PM ET
    $ACLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form S-8 POS filed by Arcellx Inc.

    S-8 POS - Arcellx, Inc. (0001786205) (Filer)

    4/28/26 4:24:11 PM ET
    $ACLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACLX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Gilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-cel

    Gilead Sciences, Inc. (NASDAQ:GILD) today announced the successful completion of its previously announced acquisition of Arcellx, Inc. (NASDAQ:ACLX). Under the terms of the transaction, Gilead acquired Arcellx for $115 per share in cash, plus one non‑transferable contingent value right (CVR) of $5 per share, representing a total implied equity value of approximately $7.8 billion at the time of closing. The acquisition builds on Kite, a Gilead Company, and Arcellx's successful collaboration and provides Gilead with full control of anitocabtagene autoleucel (anito‑cel), an investigational BCMA‑directed CAR T‑cell therapy for multiple myeloma. By consolidating ownership of anito‑cel and elim

    4/28/26 8:45:00 AM ET
    $ACLX
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Biotech Breakthroughs, Big Buyouts, Immunotherapy Momentum, and a Media Megamerger

    DENVER, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Wall Street opens to a convergence of science, scale, and strategic consolidation. From spider silk making mainstream headlines to multibillion-dollar oncology deals and accelerating immunotherapy revenues, today's tape reflects capital flowing toward platforms with validation. Kraig Biocraft Laboratories Featured on National Geographic Cover Shares of Kraig Biocraft Laboratories (OTCQB:KBLB) could see elevated interest after the company's recombinant spider silk technology landed on the cover of the March 2026 issue of National Geographic. KBLB) recombinant spider silk technology is featured on the cover of the March 2026 issue of National Geog

    2/23/26 9:36:14 AM ET
    $ACLX
    $GETY
    $IBRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Real Estate

    Gilead Sciences to Acquire Arcellx to Maximize Long-Term Potential of Anito-cel

    – Builds on Successful 2022 Collaboration on Anito-cel, a Potentially Transformative Treatment for Patients with Multiple Myeloma – – FDA Accepted Anito-cel BLA for the Treatment of Adult Patients with Relapsed/Refractory Multiple Myeloma – – Provides Gilead with Full Control of Anito-cel, Accelerating Development and Commercialization while Eliminating Profit-Share, Milestones, and Royalties – Gilead Sciences, Inc. (NASDAQ:GILD) today announced that it has entered into a definitive agreement to acquire Arcellx (NASDAQ:ACLX) for $115 per share in cash at closing and one contingent value right of $5 per share, which represents an implied equity value of $7.8 billion payable at closing.

    2/23/26 6:01:00 AM ET
    $ACLX
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACLX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Arcellx downgraded by Rothschild & Co Redburn with a new price target

    Rothschild & Co Redburn downgraded Arcellx from Buy to Neutral and set a new price target of $82.00

    2/12/26 7:20:24 AM ET
    $ACLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    UBS resumed coverage on Arcellx with a new price target

    UBS resumed coverage of Arcellx with a rating of Buy and set a new price target of $100.00

    1/7/26 9:34:38 AM ET
    $ACLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Wells Fargo initiated coverage on Arcellx with a new price target

    Wells Fargo initiated coverage of Arcellx with a rating of Overweight and set a new price target of $100.00

    12/22/25 8:37:37 AM ET
    $ACLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACLX
    Leadership Updates

    Live Leadership Updates

    View All

    Arcellx Appoints Andrew Galligan and Kristin Myers to Its Board of Directors

    -- Mr. Galligan and Ms. Myers bring decades of experience to the company board -- -- Derek Yoon steps down from the Board of Directors -- Arcellx, Inc. (NASDAQ:ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced the appointments of Andrew Galligan and Kristin Myers to its Board of Directors. Mr. Galligan is a proven financial executive who brings over three decades of strategic leadership experience to the Arcellx Board. Ms. Myers, a highly experienced healthcare industry executive, adds diverse expertise in operational execution, sales and marketing, and market

    3/20/25 4:00:00 PM ET
    $ACLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Arcellx Announces Appointment of Maryam Abdul-Kareem as General Counsel

    REDWOOD CITY, Calif., June 21, 2022 /PRNewswire/ -- Arcellx, Inc. (NASDAQ:ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced the appointment of Maryam Abdul-Kareem, J.D., as General Counsel. Ms. Abdul-Kareem brings extensive legal and business expertise in the biopharmaceutical industry, including serving in senior positions at Kinnate Biopharma and AstraZeneca. At Arcellx, she will oversee a broad spectrum of legal, contracts, and compliance matters. 

    6/21/22 4:05:00 PM ET
    $ACLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Arcellx Appoints Michelle Gilson as Chief Financial Officer

    FOSTER CITY, Calif., May 23, 2022 /PRNewswire/ -- Arcellx, Inc. (NASDAQ:ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced the appointment of Michelle Gilson as Chief Financial Officer. Ms. Gilson joins Arcellx from Canaccord Genuity, where most recently she served as Managing Director and Senior Equity Research Analyst covering biotechnology companies. Ms. Gilson will oversee the company's finance function and will play a key role in overall corporate strategy.

    5/23/22 4:05:00 PM ET
    $ACLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACLX
    Financials

    Live finance-specific insights

    View All

    Gilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-cel

    Gilead Sciences, Inc. (NASDAQ:GILD) today announced the successful completion of its previously announced acquisition of Arcellx, Inc. (NASDAQ:ACLX). Under the terms of the transaction, Gilead acquired Arcellx for $115 per share in cash, plus one non‑transferable contingent value right (CVR) of $5 per share, representing a total implied equity value of approximately $7.8 billion at the time of closing. The acquisition builds on Kite, a Gilead Company, and Arcellx's successful collaboration and provides Gilead with full control of anitocabtagene autoleucel (anito‑cel), an investigational BCMA‑directed CAR T‑cell therapy for multiple myeloma. By consolidating ownership of anito‑cel and elim

    4/28/26 8:45:00 AM ET
    $ACLX
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Arcellx and Kite Announce Strategic Collaboration to Co-Develop and Co-Commercialize Late-Stage Clinical CART-ddBCMA in Multiple Myeloma

    -- Collaboration leverages expertise across both companies, including Kite's global cell therapy leadership and industry leading reliable manufacturing -- -- Arcellx to receive $225M upfront payment; $100M equity investment; and up to $3.9B in total contingent consideration -- -- Companies to co-commercialize and split profits in the U.S.; Arcellx to receive low to mid-teen royalties outside the U.S. --   -- Arcellx to continue independently progressing its development pipeline and researching new product candidates beyond myeloma --  -- Arcellx to host a conference call and webcast today at 5:45 a.m. PT -- REDWOOD CITY, Calif., and SANTA MONICA, Calif., Dec. 9, 2022 /PRNewswire/ -- Arcellx

    12/9/22 8:15:00 AM ET
    $ACLX
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACLX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Arcellx Inc.

    SC 13G - Arcellx, Inc. (0001786205) (Subject)

    11/22/24 4:12:28 PM ET
    $ACLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Arcellx Inc.

    SC 13G/A - Arcellx, Inc. (0001786205) (Subject)

    11/14/24 4:35:36 PM ET
    $ACLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Arcellx Inc.

    SC 13G/A - Arcellx, Inc. (0001786205) (Subject)

    11/14/24 4:31:50 PM ET
    $ACLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care